What is exenatide? Structure, research and status

Exenatide is a synthetic copy of exendin-4, a Gila monster venom peptide, and in 2005 became the first FDA-approved GLP-1 receptor agonist.

Complete guide10 min read

Key takeaway

Exenatide comes from a lizard peptide, not from human GLP-1, though the two sequences partly overlap. Its only labeled use is improving blood sugar control in type 2 diabetes. In the EXSCEL trial of 14,752 adults, extended-release exenatide was noninferior to placebo for major cardiovascular events but not superior. A phase 3 trial in Parkinson's disease found no evidence that it slows the disease.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Exenatide is FDA-approved through a generic version of Byetta approved in November 2024.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited8 in this article · 8 across 1 article on Exenatide
Related productsIncretin analogs

Exenatide is a 39-amino-acid peptide that activates the same receptor as the gut hormone GLP-1. Amylin Pharmaceuticals won FDA approval for it as Byetta in April 2005, and an extended-release form, Bydureon, followed in 2012. By April 2026, FDA had withdrawn the Byetta, Bydureon and Bydureon BCise approvals at AstraZeneca's request, after the products left the market.

Quick answer: Exenatide is a GLP-1 receptor agonist peptide. Exenatide is FDA-approved through a generic version of Byetta approved in November 2024. The Byetta, Bydureon and Bydureon BCise approvals were withdrawn in 2025 and 2026 after AstraZeneca stopped marketing them. Approval covers labeled products, not research material sold under the same name.

Vitrapep does not sell exenatide; this page is a reference summary of published research and regulatory information.

What is exenatide and where did it come from?

In 1992, John Eng's team at the Bronx VA Medical Center isolated a 39-amino-acid peptide from Gila monster venom. They named it exendin-4. It differed from exendin-3, a peptide from a related lizard, at two positions [4].

In 1993, Göke and colleagues found that exendin-4 bound the GLP-1 receptor on rat insulinoma cells and raised insulin secretion from isolated rat islets. A shortened form, exendin-(9-39) amide, blocked the receptor instead [5]. These were cell and animal tissue findings. Background on the hormone itself is in Vitrapep's guide to what GLP-1 is.

The label describes exenatide as a 39-amino-acid peptide amide originally identified in Heloderma suspectum, whose sequence partially overlaps human GLP-1 [1]. FDA approved Amylin Pharmaceuticals' Byetta on April 28, 2005 (approval letter). It covered type 2 diabetes not adequately controlled on metformin, a sulfonylurea or both.

Table 1

What is exenatide and where did it come from

PropertyExenatide
ClassGLP-1 receptor agonist; a 39-amino-acid peptide amide [1]
OriginSynthetic form of exendin-4, first isolated from Gila monster venom in 1992 [1], [4]
Molecular formulaC184H282N50O60S (PubChem CID 45588096) [3]
Molecular weight4187 g/mol in PubChem; 4186.6 daltons on the label [1], [3]
EliminationMainly glomerular filtration, then proteolytic breakdown (nonclinical data) [1]
Mean terminal half-life, immediate-release form2.4 hours [1]
US brands and first approvalsByetta (April 28, 2005), Bydureon (January 27, 2012), Bydureon BCise (October 20, 2017) (Drugs@FDA)
First US genericAmneal, approved November 19, 2024, referencing Byetta (FDA)
US brand approvals withdrawnByetta as of September 3, 2025; Bydureon and Bydureon BCise as of April 8, 2026 [12], [13]
EU statusByetta authorized 2006 and Bydureon 2011; both withdrawn January 1, 2026 (EMA)

How does exenatide work?

Exenatide binds and activates the human GLP-1 receptor, according to the label's in vitro data. On pancreatic beta cells, this raises insulin synthesis and secretion through cyclic AMP and other signaling pathways [1].

The insulin effect depends on glucose: secretion rises mainly when blood glucose is elevated and subsides as it nears normal. The label states that exenatide does not impair the normal glucagon response to low blood sugar [1].

In people with type 2 diabetes, exenatide restored the first-phase insulin response, which the disease typically erases. It also lowered glucagon during high blood sugar and slowed gastric emptying. Food intake fell in animals and humans [1].

The immediate-release form is short-acting [1]. Bydureon BCise extends exposure with formulation chemistry rather than a change to the peptide. Exenatide sits inside microspheres made with a poly(D,L-lactide-co-glycolide) polymer, suspended in an oil-based vehicle. Plasma levels generally fall below the limit of measurement about 10 weeks after treatment stops [2]. Vitrapep's peptide half-life explainer compares this depot approach with fatty-acid designs.

What is exenatide approved for?

Approved uses come from section 1 of each label. Other approved peptides appear in Vitrapep's list of FDA-approved peptide medicines.

Immediate-release exenatide (Byetta and its generic) is approved, with diet and exercise, to improve glycemic control in adults with type 2 diabetes. The label advises against combining it with other exenatide-containing products [1].

Bydureon BCise carries the same indication for adults and for pediatric patients aged 10 and older [2]. FDA expanded the age range on July 22, 2021, based on the pediatric trial BCB114 (approval letter).

Neither label lists cardiovascular risk reduction or weight management in section 1 [1], [2]. Liraglutide's Victoza label, by contrast, has a cardiovascular indication (see the liraglutide complete guide).

What did the key exenatide trials show?

DeFronzo and colleagues, 2005, tested exenatide in 336 adults whose diabetes was not controlled on metformin. It ran at 82 US sites. Mean weight fell 2.8 kg and 1.6 kg in the exenatide arms. The most frequent adverse events were gastrointestinal, and no severe hypoglycemia occurred [6].

DURATION-1 (NCT00308139) compared the extended-release form with the immediate-release form in 295 adults. HbA1c of 7.0% or less was reached by 77% versus 61% of evaluable patients [7].

EXSCEL (NCT01144338) added extended-release exenatide or placebo to usual care. Of 14,752 adults, 73.1% had prior cardiovascular disease, and median follow-up was 3.2 years. Rates of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma and serious adverse events did not differ significantly [8].

BCB114 (NCT01554618) randomized 83 youths aged 10 to under 18 with type 2 diabetes. Adverse events occurred in 61.0% on exenatide and 73.9% on placebo [9].

Table 2

What did the key exenatide trials show

TrialPopulation and sizeDesign and lengthPrimary result
DeFronzo et al., 2005 [6]336 adults with type 2 diabetes on metforminTriple-blind, placebo-controlled; 30 weeksHbA1c fell 0.78 and 0.40 points in the exenatide arms vs rose 0.08 on placebo
DURATION-1, 2008 [7]295 adults with type 2 diabetesRandomized, open-label, noninferiority; 30 weeksHbA1c fell 1.9 points (extended-release) vs 1.5 (immediate-release); difference significant, p=0.0023
EXSCEL, 2017 [8]14,752 adults with type 2 diabetesDouble-blind, placebo-controlled; median 3.2 yearsMajor cardiovascular events 11.4% vs 12.2%; hazard ratio 0.91 (95% CI, 0.83 to 1.00); noninferior, not superior
Tamborlane et al., 2022 [9]83 youths aged 10 to under 18Double-blind, placebo-controlled; 24 weeksHbA1c fell 0.36 points vs rose 0.49; difference 0.85 points (95% CI, 0.19 to 1.51)

All four are human randomized trials. Vitrapep's guide on how to find a peptide clinical trial explains how to read these registry records.

What else has exenatide been studied for?

Preclinical models suggested exenatide might protect neurons, so researchers tested it in Parkinson's disease [10].

A single-center phase 2 trial by Athauda and colleagues (NCT01971242) enrolled 62 patients with moderate disease. Treatment lasted 48 weeks, followed by a 12-week washout. Off-medication motor scores differed by 3.5 points in favor of exenatide at 60 weeks. The authors said it was uncertain whether this reflected disease modification or lasting symptom effects [10].

The phase 3 Exenatide-PD3 trial (NCT04232969) tested that question at six UK hospitals. It randomized 194 participants for 96 weeks. Motor scores worsened by 5.7 points on exenatide and 4.5 on placebo, with no significant difference. Serious adverse events occurred in 9% versus 11%. The authors found no evidence for exenatide as a disease-modifying treatment [11].

NLY01, a pegylated exenatide, is in a phase 2 multiple sclerosis trial (NCT07497399), recruiting an estimated 120 adults. Exendin-4 also anchors radiotracers being compared for locating insulinomas on PET scans (NCT07808879).

What side effects do the exenatide labels list?

Immediate-release exenatide carries no boxed warning. Its most common reactions, each at least 5%, are nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation and asthenia. Nausea usually decreases over time. Nausea (3%) and vomiting (1%) were the most common reasons for withdrawal [1].

Table 3

What side effects do the exenatide labels list

Adverse reactionExenatide, % (N=963)Placebo, % (N=483)
Nausea4418
Vomiting134
Diarrhea136
Feeling jittery94
Dizziness96
Headache96
Dyspepsia63
Asthenia42

Source: exenatide label, Table 3, three 30-week placebo-controlled trials with metformin, a sulfonylurea or both [1]. In the sulfonylurea trial, hypoglycemia occurred in 14.4% and 35.7% of the exenatide arms versus 3.3% on placebo [1].

Boxed warning for Bydureon BCise. Extended-release exenatide increased thyroid C-cell tumors in rats at clinically relevant exposures. Whether it causes such tumors in humans, including medullary thyroid carcinoma, is unknown. It is contraindicated with a personal or family history of that cancer or with MEN 2 [2]. Its most common reactions were injection-site nodules (10.5%) and nausea (8.2%) among 526 adults [2].

Shared warnings. Both labels warn of acute pancreatitis, including fatal hemorrhagic or necrotizing cases. They also warn of acute kidney injury from dehydration, severe gastrointestinal reactions and serious hypersensitivity. Other warnings cover hypoglycemia with insulin or sulfonylureas, gallbladder disease and pulmonary aspiration during anesthesia [1], [2]. Drug-induced immune thrombocytopenia has been linked to serious, sometimes fatal bleeding. Exenatide-dependent antibodies destroy platelets, and the labels say affected patients should not be re-exposed [1]. In the 30-week trials, 6% developed higher-titer antibodies, and 3% overall had a weaker glucose response [1]. Bydureon labeling adds serious injection-site reactions, including abscess and necrosis [2].

On November 9, 2026, FDA required all GLP-1 receptor agonist labels to warn of a possible increased NAION risk. NAION is a rare optic nerve condition. FDA's list includes Byetta, its earliest entry, from 2005. Pooled data from 126 trials showed 6.4 cases per 100,000 person-years versus 3.8 with comparators [14]. The exenatide labels on DailyMed did not show the warning on November 18, 2026. See Vitrapep's summary of FDA's GLP-1 eye-risk warning.

What is the regulatory status of exenatide?

Brand withdrawals. AstraZeneca told FDA the products were no longer marketed and asked for withdrawal. Approval of Byetta ended on September 3, 2025 [12]. Bydureon, Bydureon Pen and Bydureon BCise followed on April 8, 2026 [13]. On November 13, 2026, FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons. Generics referencing it are unaffected (Federal Register).

Generic supply. FDA's November 2026 safety communication says only generic exenatide products are marketed [14]. On November 18, 2026, Drugs@FDA listed Amneal's generic as discontinued (Drugs@FDA). FDA's own records therefore do not agree on current US supply.

A refused product. In August 2024, FDA refused to approve ITCA 650, exenatide in the DUROS device. FDA found that Intarcia had not shown the product was safe for its intended use (Federal Register).

Europe and sport. The European Commission withdrew Byetta and Bydureon on January 1, 2026, at AstraZeneca's request for commercial reasons. The WADA 2026 Prohibited List does not name exenatide or GLP-1 receptor agonists.

Research-labeled products. FDA's page on unapproved GLP-1 drugs names five compounds sold falsely "for research purposes." Exenatide is not among them. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

What is still unknown about exenatide?

The human relevance of the rat thyroid tumors has not been determined [2]. AstraZeneca's EXCEED study (NCT05663515) is comparing pancreatic cancer rates in an estimated 24,000 European patients. FDA found no animal mechanism for NAION [14]. In Parkinson's disease, the PD3 authors called for agents with better target engagement [11].

Frequently asked questions

Is exenatide a peptide?

Yes. The label describes it as a 39-amino-acid synthetic peptide amide.

Does exenatide come from Gila monster venom?

The medicine is made synthetically. Its sequence matches exendin-4, which was first isolated from Gila monster venom in 1992.

Is Byetta still approved in the US?

No. FDA withdrew the Byetta approval as of September 3, 2025, at AstraZeneca's request. A generic approved in November 2024 remains approved.

What is the difference between Byetta and Bydureon?

Both contain exenatide. Byetta is the immediate-release form. Bydureon BCise, an extended-release form, holds exenatide in polymer microspheres and carries a boxed warning about thyroid C-cell tumors in rats.

Did exenatide work in Parkinson's disease?

A 62-patient phase 2 trial reported better motor scores. The 194-participant phase 3 trial found no evidence that exenatide slows the disease.

Is research-grade exenatide FDA-approved?

No. FDA approval applies to labeled products made under approved applications. Material sold for laboratory research is not an approved medicine.

What to know now

  • Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide from Gila monster venom.
  • Its only labeled use is glycemic control in type 2 diabetes; EXSCEL showed cardiovascular noninferiority, not superiority.
  • FDA withdrew the Byetta, Bydureon and Bydureon BCise approvals in 2025 and 2026 at AstraZeneca's request; a generic remains approved.

What we’re watching

  • NAION warning text appearing on exenatide labels after FDA's November 2026 requirement.
  • Results of the EXCEED pancreatic cancer safety study.
  • Whether generic exenatide stays on the US market, given conflicting FDA records.

More for endocrine & metabolism

All 48 compounds for endocrine & metabolism

Sources: U.S. National Library of Medicine 2026; U.S. Food and Drug Administration 2025; National Center for Biotechnology Information 2026; Eng 1992, Journal of Biological Chemistry, 267; Göke 1993, Journal of Biological Chemistry, 268; DeFronzo 2005, Diabetes Care, 28; Drucker 2008, Lancet, 372; Holman 2017, New England Journal of Medicine, 377; Tamborlane 2022, Diabetes Care, 45; Athauda 2017, Lancet, 390; Vijiaratnam 2025, Lancet, 405; Food and Drug Administration 2025, Federal Register; Food and Drug Administration 2026, Federal Register; U.S. Food and Drug Administration 2026. All 14 citations

Back to the research library

References

  1. U.S. National Library of Medicine. (2026). Exenatide injection (Amneal Pharmaceuticals): prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949
  2. U.S. Food and Drug Administration. (2025). Bydureon BCise (exenatide extended-release) injectable suspension: prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209210s025lbl.pdf
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 45588096, exenatide. https://pubchem.ncbi.nlm.nih.gov/compound/45588096
  4. Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry, 267(11), 7402-7405. https://pubmed.ncbi.nlm.nih.gov/1313797/
  5. Göke, R., Fehmann, H. C., Linn, T., et al. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. Journal of Biological Chemistry, 268(26), 19650-19655. https://pubmed.ncbi.nlm.nih.gov/8396143/
  6. DeFronzo, R. A., Ratner, R. E., Han, J., et al. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28(5), 1092-1100. https://doi.org/10.2337/diacare.28.5.1092
  7. Drucker, D. J., Buse, J. B., Taylor, K., et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet, 372(9645), 1240-1250. https://doi.org/10.1016/S0140-6736(08)61206-4
  8. Holman, R. R., Bethel, M. A., Mentz, R. J., et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 377(13), 1228-1239. https://doi.org/10.1056/NEJMoa1612917
  9. Tamborlane, W. V., Bishai, R., Geller, D., et al. (2022). Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care, 45(8), 1833-1840. https://doi.org/10.2337/dc21-2275
  10. Athauda, D., Maclagan, K., Skene, S. S., et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, 390(10103), 1664-1675. https://doi.org/10.1016/S0140-6736(17)31585-4
  11. Vijiaratnam, N., Girges, C., Auld, G., et al. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet, 405(10479), 627-636. https://doi.org/10.1016/S0140-6736(24)02808-3
  12. Food and Drug Administration. (2025). Teva Branded Pharmaceutical Products R&D, Inc., et al.; withdrawal of approval of 39 new drug applications. Federal Register, FR Doc. 2025-14683. https://www.federalregister.gov/documents/2025/08/04/2025-14683/teva-branded-pharmaceutical-products-randd-inc-et-al-withdrawal-of-approval-of-39-new-drug
  13. Food and Drug Administration. (2026). Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; withdrawal of approval of 46 new drug applications. Federal Register, FR Doc. 2026-04546. https://www.federalregister.gov/documents/2026/03/09/2026-04546/aspen-global-inc-co-lachman-consultant-services-inc-et-al-withdrawal-of-approval-of-46-new-drug
  14. U.S. Food and Drug Administration. (2026). FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential